Sumanta K. Pal, MD, FASCO, on Moving Forward with Cabozantinib as Treatment for Patients with RCC

Video

Pal discussed the emergence of cabozantinib as a treatment option for patients with renal cell carcinoma and touched on future research around the drug.

Sumanta K. Pal, MD, FASCO, spoke with CancerNetwork® regarding the emergence of cabozantinib (Cabometyx) as a treatment option for patients with renal cell carcinoma and discussed future research around the drug from an abstract on the SWOG 1500 trial (NCT02761057) at the 2021 Genitourinary Cancers Symposium.

Transcription:

From here on out, it’s going to be the infrequent patient that receives sunitinib (Sutent) in the frontline setting, outside of perhaps clinical trials. I think that cabozantinib probably should be the gold standard. The big question that emerges is ‘do we combine cabozantinib with immunotherapy now that we can do that for these patients,’ and I would suggest some pause. I would suggest that perhaps it’s better for us to wait until we have randomized data. To that end, we are moving forward with a clinical trial of cabozantinib plus or minus immunotherapy in patients with papillary kidney cancer within the cooperative groups. Once again, it’s a trial…looking at that combination of agents.

Reference:

Pal SK, Tangen C, Thompson IM, et al. Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study. Presented at: 2021 Genitourinary Cancers Symposium. Abstract 270.

Recent Videos
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content